SLC5A2 and metabolic dysfunction-associated steatohepatitis: Numerous clinical trials and meta‐analyses now validate that SGLT2 inhibitors can diminish liver fat and inhibit fibrosis progression in patients with MASLD [44, 64, 65, 66], rendering them a compelling choice, particularly for MASH patients with concurrent type 2 diabetes.